Replies to post #22981 on Cytodyn Inc (CYDY)

[buckysherm]

You have been silent on all of IHub for a year and half and you come here to say this. Interesting.

[finesand]

gold- if you make this analogy to Pro140,
they would needed to have falsified a lot of data and research.

Sounds more a KTOV story to me here, than CYDY.

However, not closing a blind eye to negative statements,
would you be so kind and provide a little timetable plus some links for our own validation of Mr Burger's credibility?
That would be a good question to Mr Nader, if there is anything to it.

When did the fraud at Biocurex happen? More details please.
Still, I doubt all those papers & data of Pro140 for more than ten years are impacted in any way here.
Nonetheless will dig into Mr Burger's potential involvement - even if he was guilty, it must not mean that he falsified Pro140 data and papers being produced by others - sure not.
You might have noticed the April'18 CD01-Ext Monotrial paper, not even 'pumping' the result at all.
Too many are involved here.

+++

- Biocurex delisted 2013-2014?
- https://investorshub.advfn.com/BioCurex-Inc(fka-BOCX)-2475/

+++

Mr Burger
- https://www.bloomberg.com/research/stocks/private/person.asp?personId=362586&privcapId=10039157
-- Biocurex Executive Chairman: 2009-Present
-- CYDY 2014-present

CYDY Current Science Board https://www.cytodyn.com/media/press-releases/detail/273/cytodyn-forms-scientific-advisory-board-to-advance-pro-140

CYDY Current BOD https://www.cytodyn.com/about-cytodyn/board-of-directors

Mr Burger @ CYDY

Dr. Burger was appointed a Director in February 2014, named Vice Chairman in August 2014 and Chief Science Officer in January 2016. He is a life sciences executive with over 30 years of extensive scientific, operational and financial experience in the biotech industry. As CEO or chairman of several biotechnology companies, Dr. Burger has led numerous corporate financing transactions and public securities offerings and has experience leading R&D, GMP manufacturing and clinical development functional areas. Dr. Burger is currently a Director of Aptose Biosciences Inc., a cancer therapeutics, NASDAQ-listed company. Dr. Burger co-founded Trinity Biotech, a NASDAQ-listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, and is currently lead independent director. Until March 2007, he was Chairman and Chief Executive Officer of AVI Biopharma Inc. (now Sarepta Therapeutics), a NASDAQ listed RNA therapeutics company. He was also a co-founder of Epitope Inc. (now Orasure Technologies, NASDAQ listed), serving as its Chairman from 1981 to 1990. Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health and Sciences University in Portland. Dr. Burger received his undergraduate degree in Bacteriology and Immunology from the University of California in Berkeley and his Master of Science and Ph.D. degrees in Microbiology and Immunology from the University of Arizona.

Mr Burger @ Biocurex

Dr. Dennis Berger - Chairman of the Board
On September 8, 2009, the BioCurex Board of Directors elected Dr. Denis Burger to the executive office of Executive Chairman of the Company.
Prior to joining BioCurex, he had been Managing Director of Paradigm Ventures, LLC, a biotech investing and consulting firm, since 1991. He was
Chairman and CEO of AVI BioPharma, Inc., a drug development company using gene targeted therapeutics, from 1997 to 2007 and founding
Chairman of Epitope, Inc., a developer of diagnostic products from 1981 to 1990. He is currently a director of Trinity Biotech PLC, a diagnostic
products developer, and Lorus Therapeutics, a cancer therapeutics company.